dc.contributor.author |
Lee, Kevin |
en |
dc.contributor.author |
Goodman, Lucy |
en |
dc.contributor.author |
Fourie, Chantelle |
en |
dc.contributor.author |
Schenk, S |
en |
dc.contributor.author |
Leitch, B |
en |
dc.contributor.author |
Montgomery, Johanna |
en |
dc.contributor.editor |
Donev, Rossen |
en |
dc.date.accessioned |
2017-10-16T03:04:10Z |
en |
dc.date.issued |
2016-01 |
en |
dc.identifier.citation |
In Advances in protein chemistry and structural biology. Editors: Donev R. 103: 203-261. Elsevier Jan 2016 |
en |
dc.identifier.isbn |
978-0-12-804794-1 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/36087 |
en |
dc.description.abstract |
Almost every neurological disease directly or indirectly affects synapse function in the brain. However, these diseases alter synapses through different mechanisms, ultimately resulting in altered synaptic transmission and/or plasticity. Glutamate is the major neurotransmitter that mediates excitatory synaptic transmission in the brain through activation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors. These receptors have therefore been identified as a target for the development of therapeutic treatments for neurological disorders including epilepsy, neurodegenerative diseases, autism, and drug addiction. The fact that AMPA receptors play a dominant role throughout the brain raises the significant challenge of selectively targeting only those regions affected by disease, and clinical trials have raised doubt regarding the feasibility of specifically targeting AMPA receptors for new therapeutic options. Benzamide compounds that act as positive allosteric AMPA receptor modulators, known as AMPAkines, can act on specific brain regions and were initially proposed to revolutionize the treatment of cognitive deficits associated with neurological disorders. Their therapeutic potential has since declined due to inconsistent results in clinical trials. However, recent advances in basic biomedical research are significantly increasing our knowledge of AMPA receptor structure, binding sites, and interactions with auxiliary proteins. In particular, the large complex of postsynaptic proteins that interact with AMPA receptor subunits have been shown to control AMPA receptor insertion, location, pharmacology, synaptic transmission, and plasticity. These proteins are now being considered as alternative therapeutic target sites for modulating AMPA receptors in neurological disorders. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.publisher |
Elsevier |
en |
dc.relation.ispartof |
Advances in protein chemistry and structural biology |
en |
dc.relation.ispartofseries |
Advances in protein chemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Brain |
en |
dc.subject |
Humans |
en |
dc.subject |
Nervous System Diseases |
en |
dc.subject |
Epilepsy |
en |
dc.subject |
Benzamides |
en |
dc.subject |
Receptors, AMPA |
en |
dc.subject |
Synaptic Transmission |
en |
dc.subject |
Neuronal Plasticity |
en |
dc.subject |
Molecular Targeted Therapy |
en |
dc.title |
AMPA receptors as therapeutic targets for neurological disorders |
en |
dc.type |
Book Item |
en |
dc.identifier.doi |
10.1016/bs.apcsb.2015.10.004 |
en |
pubs.begin-page |
203 |
en |
pubs.volume |
103 |
en |
dc.rights.holder |
Copyright: Elsevier |
en |
dc.identifier.pmid |
26920691 |
en |
pubs.end-page |
261 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.elements-id |
508034 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Physiology Division |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Obstetrics and Gynaecology |
en |
pubs.number |
6 |
en |
pubs.record-created-at-source-date |
2017-10-16 |
en |
pubs.dimensions-id |
26920691 |
en |